Filing Flows › Vertex Pharmaceuticals (VRTX) › Free cash flow
Vertex Pharmaceuticals (VRTX) free cash flow by quarter
Vertex Pharmaceuticals' free cash flow was $546M in Q3 2026 (third quarter 2026), -46% from Q2 2026. Over the last 7 quarters it ranged from $349M (Q4 2025) to $1.3B (Q1 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $546M | -46% | -52% |
| Q2 2026 | $1.0B | -22% | +9% |
| Q1 2026 | $1.3B | +271% | +66% |
| Q4 2025 | $349M | -69% | — |
| Q3 2025 | $1.1B | +23% | — |
| Q2 2025 | $927M | +19% | — |
| Q1 2025 | $778M | — | — |
Q3 2026 at a glance
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vertex Pharmaceuticals' free cash flow?
Vertex Pharmaceuticals' free cash flow was $546M in Q3 2026 (third quarter 2026), -46% from Q2 2026.
How has Vertex Pharmaceuticals' free cash flow changed?
Over the last 7 quarters it ranged from $349M (Q4 2025) to $1.3B (Q1 2026).
Q3 2026 results → · How Vertex Pharmaceuticals makes money →